Browsing Tag
Viatris
13 posts
Biocon goes all-in on biosimilars with $5.5bn Biocon Biologics merger and Viatris exit
Biocon to merge Biocon Biologics in $5.5B deal with full ownership via share swap and cash. Find out what it means for investors and global biosimilar strategy.
Phase 2 trial of Nasus Pharma’s NS002 needle-free epinephrine starts with initial dosing milestone
Find out how Nasus Pharma is advancing NS002, its needle-free intranasal epinephrine candidate, into Phase 2 trials and what it means for emergency allergy care.
Safecor Health to acquire UDL from Viatris to expand pharmaceutical unit-dose solutions
Safecor Health, a leader in pharmaceutical unit-dose repackaging and supply chain solutions, has announced its acquisition of the…
Sandoz and Biocon Biologics sign distribution deal for key immunology drug
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd and a prominent player in the global biosimilars market,…
Biocon Biologics wraps up integration of Viatris’ biosimilars business in Europe
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful completion of the integration of…
Viatris Inc. announces divestitures in key business sectors: Comprehensive breakdown
Viatris Inc. (NASDAQ: VTRS), a frontrunner in global healthcare, has unveiled a series of divestitures in its business…
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars…
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability…
Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the…
Can Unichem Laboratories’ FDA approval for generic Dilantin boost its US epilepsy drug portfolio?
Unichem Laboratories wins US FDA approval for its generic Dilantin capsules to treat seizures, expanding its US neurology portfolio.